Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
BiologicsMolecular Targeted Therapeutics

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1791470

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1791470

Antibody Drug Conjugates Contract Manufacturing

PUBLISHED:
PAGES: 168 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 5850
PDF (Global License to Company and its Fully-owned Subsidiaries)
USD 17550

Add to Cart

Description

Table of Contents

Global Antibody Drug Conjugates Contract Manufacturing Market to Reach US$29.1 Billion by 2030

The global market for Antibody Drug Conjugates Contract Manufacturing estimated at US$13.4 Billion in the year 2024, is expected to reach US$29.1 Billion by 2030, growing at a CAGR of 13.8% over the analysis period 2024-2030. Myeloma Condition, one of the segments analyzed in the report, is expected to record a 15.5% CAGR and reach US$16.0 Billion by the end of the analysis period. Growth in the Lymphome Condition segment is estimated at 12.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$3.5 Billion While China is Forecast to Grow at 12.9% CAGR

The Antibody Drug Conjugates Contract Manufacturing market in the U.S. is estimated at US$3.5 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$4.5 Billion by the year 2030 trailing a CAGR of 12.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 12.9% and 11.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 9.9% CAGR.

Global Antibody Drug Conjugates (ADC) Contract Manufacturing Market - Key Trends & Drivers Summarized

Why Are Antibody Drug Conjugates Gaining Traction in the Pharmaceutical Industry?

Antibody-drug conjugates (ADCs) have emerged as a revolutionary class of targeted therapies, combining the specificity of monoclonal antibodies with the potency of cytotoxic drugs. These innovative biopharmaceuticals are transforming oncology treatment paradigms, offering precise tumor-targeting capabilities with reduced systemic toxicity. The rise of personalized medicine and the growing understanding of cancer biology have fueled the development of ADCs, making them one of the fastest-growing segments in the biologics market. Unlike conventional chemotherapy, ADCs selectively deliver cytotoxic payloads to cancer cells while sparing healthy tissues, significantly improving treatment outcomes. As pharmaceutical companies intensify their focus on ADC-based therapies, the demand for specialized contract manufacturing organizations (CMOs) with expertise in biologics, conjugation chemistry, and high-potency drug handling is surging.

What Technological Advances Are Enhancing the Development of ADCs?

The rapid evolution of antibody-drug conjugate technology is driven by advancements in linker chemistry, payload optimization, and site-specific conjugation techniques. Modern ADCs are benefiting from improved linker stability, ensuring that the cytotoxic payload is released only upon reaching the target cells. Additionally, innovative payloads with higher potency and selectivity, such as pyrrolobenzodiazepine (PBD) dimers and tubulin inhibitors, are expanding the therapeutic applications of ADCs. Site-specific conjugation technologies, including THIOMAB and glycoengineering approaches, are enhancing drug-to-antibody ratio (DAR) control, leading to more homogenous and effective ADC formulations. AI-driven drug discovery and bioprocess optimization are further streamlining ADC development, allowing for faster and more cost-effective production.

Which Companies and Regions Are Leading the ADC Contract Manufacturing Market?

The global ADC contract manufacturing market is witnessing a surge in investments, with leading CMOs and biotechnology firms scaling up their capabilities to meet industry demand. The United States remains a dominant player in ADC manufacturing, with contract development and manufacturing organizations (CDMOs) such as Lonza, Catalent, and WuXi Biologics investing in high-containment facilities for ADC production. Europe and Asia-Pacific are also witnessing rapid expansion, with countries like Switzerland, Germany, China, and South Korea emerging as key hubs for ADC contract manufacturing. The rising number of biotech startups focused on ADC development has further intensified the need for reliable outsourcing partners, fostering collaborations between pharmaceutical giants and specialized CMOs.

What Are the Market Forces Driving the Growth of ADC Contract Manufacturing?

The growth in the ADC contract manufacturing market is driven by several factors, including the rising adoption of targeted cancer therapies, advancements in bioconjugation technology, and the increasing complexity of ADC production processes. The shift towards outsourcing manufacturing due to high infrastructure costs and stringent regulatory requirements has propelled demand for specialized CDMOs. Additionally, the expansion of clinical pipelines for ADC-based therapies, particularly in oncology and autoimmune diseases, is fueling market growth. The growing emphasis on Good Manufacturing Practice (GMP)-compliant production, along with stringent regulatory oversight from agencies like the FDA and EMA, has further increased the reliance on experienced contract manufacturers. Moreover, the ongoing research into next-generation ADCs, including dual-drug conjugates and immune-modulating ADCs, is expected to create new opportunities in the contract manufacturing space. As ADCs continue to revolutionize targeted therapy, contract manufacturers are poised to play a pivotal role in shaping the future of biopharmaceutical innovation.

SCOPE OF STUDY:

The report analyzes the Antibody Drug Conjugates Contract Manufacturing market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Condition Type (Myeloma Condition, Lymphome Condition, Other Conditions); Linker (Cleavable Linker, Non-Cleavable Linker)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 36 Featured) -

  • AbbVie Contract Manufacturing
  • Abzena
  • AGC Biologics
  • Axplora Group GmbH
  • ChemExpress
  • EirGenix, Inc.
  • MilliporeSigma
  • Piramal Pharma Solutions
  • Single Use Support GmbH
  • Sterling Pharma Solutions Limited
  • Veranova
  • WuXi Biologics

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Show more
Product Code: MCP29179

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Antibody Drug Conjugates Contract Manufacturing - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Growing Demand for Targeted Cancer Therapies Driving ADC Market Expansion
    • Expansion of Biopharma Outsourcing for ADC Development and Manufacturing
    • Rising Investments in Novel ADC Linker Technologies for Enhanced Drug Efficacy
    • Surge in Demand for High-Potency Active Pharmaceutical Ingredients (HPAPIs) in ADCs
    • Advancements in Site-Specific Conjugation Technologies for Improved Stability
    • Increasing Adoption of AI and Big Data Analytics in ADC Development
    • Expansion of Bioconjugation and Next-Generation Payload Technologies
    • Growing Strategic Collaborations Between Pharma Companies and ADC Manufacturers
    • Increasing Focus on Scalable and Cost-Effective ADC Manufacturing Solutions
    • Rising Demand for Fully Integrated ADC Manufacturing Services
    • Advancements in ADC Formulation Technologies for Enhanced Drug Delivery
    • Surge in Investments for Expanding ADC Manufacturing Capacity Worldwide
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Antibody Drug Conjugates Contract Manufacturing Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Antibody Drug Conjugates Contract Manufacturing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Antibody Drug Conjugates Contract Manufacturing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Antibody Drug Conjugates Contract Manufacturing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Myeloma Condition by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Myeloma Condition by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Myeloma Condition by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Lymphome Condition by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Lymphome Condition by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Lymphome Condition by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Other Conditions by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Other Conditions by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Other Conditions by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Cleavable Linker by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Cleavable Linker by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Cleavable Linker by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Non-Cleavable Linker by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Non-Cleavable Linker by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Non-Cleavable Linker by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Antibody Drug Conjugates Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 20: USA Recent Past, Current & Future Analysis for Antibody Drug Conjugates Contract Manufacturing by Condition Type - Myeloma Condition, Lymphome Condition and Other Conditions - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Antibody Drug Conjugates Contract Manufacturing by Condition Type - Myeloma Condition, Lymphome Condition and Other Conditions Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: USA 15-Year Perspective for Antibody Drug Conjugates Contract Manufacturing by Condition Type - Percentage Breakdown of Value Sales for Myeloma Condition, Lymphome Condition and Other Conditions for the Years 2015, 2025 & 2030
    • TABLE 23: USA Recent Past, Current & Future Analysis for Antibody Drug Conjugates Contract Manufacturing by Linker - Cleavable Linker and Non-Cleavable Linker - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Antibody Drug Conjugates Contract Manufacturing by Linker - Cleavable Linker and Non-Cleavable Linker Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: USA 15-Year Perspective for Antibody Drug Conjugates Contract Manufacturing by Linker - Percentage Breakdown of Value Sales for Cleavable Linker and Non-Cleavable Linker for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Antibody Drug Conjugates Contract Manufacturing by Condition Type - Myeloma Condition, Lymphome Condition and Other Conditions - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for Antibody Drug Conjugates Contract Manufacturing by Condition Type - Myeloma Condition, Lymphome Condition and Other Conditions Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: Canada 15-Year Perspective for Antibody Drug Conjugates Contract Manufacturing by Condition Type - Percentage Breakdown of Value Sales for Myeloma Condition, Lymphome Condition and Other Conditions for the Years 2015, 2025 & 2030
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Antibody Drug Conjugates Contract Manufacturing by Linker - Cleavable Linker and Non-Cleavable Linker - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Antibody Drug Conjugates Contract Manufacturing by Linker - Cleavable Linker and Non-Cleavable Linker Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: Canada 15-Year Perspective for Antibody Drug Conjugates Contract Manufacturing by Linker - Percentage Breakdown of Value Sales for Cleavable Linker and Non-Cleavable Linker for the Years 2015, 2025 & 2030
  • JAPAN
    • Antibody Drug Conjugates Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Antibody Drug Conjugates Contract Manufacturing by Condition Type - Myeloma Condition, Lymphome Condition and Other Conditions - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for Antibody Drug Conjugates Contract Manufacturing by Condition Type - Myeloma Condition, Lymphome Condition and Other Conditions Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: Japan 15-Year Perspective for Antibody Drug Conjugates Contract Manufacturing by Condition Type - Percentage Breakdown of Value Sales for Myeloma Condition, Lymphome Condition and Other Conditions for the Years 2015, 2025 & 2030
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Antibody Drug Conjugates Contract Manufacturing by Linker - Cleavable Linker and Non-Cleavable Linker - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Antibody Drug Conjugates Contract Manufacturing by Linker - Cleavable Linker and Non-Cleavable Linker Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: Japan 15-Year Perspective for Antibody Drug Conjugates Contract Manufacturing by Linker - Percentage Breakdown of Value Sales for Cleavable Linker and Non-Cleavable Linker for the Years 2015, 2025 & 2030
  • CHINA
    • Antibody Drug Conjugates Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 38: China Recent Past, Current & Future Analysis for Antibody Drug Conjugates Contract Manufacturing by Condition Type - Myeloma Condition, Lymphome Condition and Other Conditions - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: China Historic Review for Antibody Drug Conjugates Contract Manufacturing by Condition Type - Myeloma Condition, Lymphome Condition and Other Conditions Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: China 15-Year Perspective for Antibody Drug Conjugates Contract Manufacturing by Condition Type - Percentage Breakdown of Value Sales for Myeloma Condition, Lymphome Condition and Other Conditions for the Years 2015, 2025 & 2030
    • TABLE 41: China Recent Past, Current & Future Analysis for Antibody Drug Conjugates Contract Manufacturing by Linker - Cleavable Linker and Non-Cleavable Linker - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Antibody Drug Conjugates Contract Manufacturing by Linker - Cleavable Linker and Non-Cleavable Linker Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: China 15-Year Perspective for Antibody Drug Conjugates Contract Manufacturing by Linker - Percentage Breakdown of Value Sales for Cleavable Linker and Non-Cleavable Linker for the Years 2015, 2025 & 2030
  • EUROPE
    • Antibody Drug Conjugates Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 44: Europe Recent Past, Current & Future Analysis for Antibody Drug Conjugates Contract Manufacturing by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 45: Europe Historic Review for Antibody Drug Conjugates Contract Manufacturing by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Europe 15-Year Perspective for Antibody Drug Conjugates Contract Manufacturing by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Antibody Drug Conjugates Contract Manufacturing by Condition Type - Myeloma Condition, Lymphome Condition and Other Conditions - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Antibody Drug Conjugates Contract Manufacturing by Condition Type - Myeloma Condition, Lymphome Condition and Other Conditions Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: Europe 15-Year Perspective for Antibody Drug Conjugates Contract Manufacturing by Condition Type - Percentage Breakdown of Value Sales for Myeloma Condition, Lymphome Condition and Other Conditions for the Years 2015, 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Antibody Drug Conjugates Contract Manufacturing by Linker - Cleavable Linker and Non-Cleavable Linker - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Antibody Drug Conjugates Contract Manufacturing by Linker - Cleavable Linker and Non-Cleavable Linker Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Europe 15-Year Perspective for Antibody Drug Conjugates Contract Manufacturing by Linker - Percentage Breakdown of Value Sales for Cleavable Linker and Non-Cleavable Linker for the Years 2015, 2025 & 2030
  • FRANCE
    • Antibody Drug Conjugates Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 53: France Recent Past, Current & Future Analysis for Antibody Drug Conjugates Contract Manufacturing by Condition Type - Myeloma Condition, Lymphome Condition and Other Conditions - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: France Historic Review for Antibody Drug Conjugates Contract Manufacturing by Condition Type - Myeloma Condition, Lymphome Condition and Other Conditions Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: France 15-Year Perspective for Antibody Drug Conjugates Contract Manufacturing by Condition Type - Percentage Breakdown of Value Sales for Myeloma Condition, Lymphome Condition and Other Conditions for the Years 2015, 2025 & 2030
    • TABLE 56: France Recent Past, Current & Future Analysis for Antibody Drug Conjugates Contract Manufacturing by Linker - Cleavable Linker and Non-Cleavable Linker - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Antibody Drug Conjugates Contract Manufacturing by Linker - Cleavable Linker and Non-Cleavable Linker Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: France 15-Year Perspective for Antibody Drug Conjugates Contract Manufacturing by Linker - Percentage Breakdown of Value Sales for Cleavable Linker and Non-Cleavable Linker for the Years 2015, 2025 & 2030
  • GERMANY
    • Antibody Drug Conjugates Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 59: Germany Recent Past, Current & Future Analysis for Antibody Drug Conjugates Contract Manufacturing by Condition Type - Myeloma Condition, Lymphome Condition and Other Conditions - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Germany Historic Review for Antibody Drug Conjugates Contract Manufacturing by Condition Type - Myeloma Condition, Lymphome Condition and Other Conditions Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Germany 15-Year Perspective for Antibody Drug Conjugates Contract Manufacturing by Condition Type - Percentage Breakdown of Value Sales for Myeloma Condition, Lymphome Condition and Other Conditions for the Years 2015, 2025 & 2030
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Antibody Drug Conjugates Contract Manufacturing by Linker - Cleavable Linker and Non-Cleavable Linker - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Antibody Drug Conjugates Contract Manufacturing by Linker - Cleavable Linker and Non-Cleavable Linker Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: Germany 15-Year Perspective for Antibody Drug Conjugates Contract Manufacturing by Linker - Percentage Breakdown of Value Sales for Cleavable Linker and Non-Cleavable Linker for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 65: Italy Recent Past, Current & Future Analysis for Antibody Drug Conjugates Contract Manufacturing by Condition Type - Myeloma Condition, Lymphome Condition and Other Conditions - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Italy Historic Review for Antibody Drug Conjugates Contract Manufacturing by Condition Type - Myeloma Condition, Lymphome Condition and Other Conditions Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Italy 15-Year Perspective for Antibody Drug Conjugates Contract Manufacturing by Condition Type - Percentage Breakdown of Value Sales for Myeloma Condition, Lymphome Condition and Other Conditions for the Years 2015, 2025 & 2030
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Antibody Drug Conjugates Contract Manufacturing by Linker - Cleavable Linker and Non-Cleavable Linker - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Antibody Drug Conjugates Contract Manufacturing by Linker - Cleavable Linker and Non-Cleavable Linker Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Italy 15-Year Perspective for Antibody Drug Conjugates Contract Manufacturing by Linker - Percentage Breakdown of Value Sales for Cleavable Linker and Non-Cleavable Linker for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Antibody Drug Conjugates Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 71: UK Recent Past, Current & Future Analysis for Antibody Drug Conjugates Contract Manufacturing by Condition Type - Myeloma Condition, Lymphome Condition and Other Conditions - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: UK Historic Review for Antibody Drug Conjugates Contract Manufacturing by Condition Type - Myeloma Condition, Lymphome Condition and Other Conditions Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: UK 15-Year Perspective for Antibody Drug Conjugates Contract Manufacturing by Condition Type - Percentage Breakdown of Value Sales for Myeloma Condition, Lymphome Condition and Other Conditions for the Years 2015, 2025 & 2030
    • TABLE 74: UK Recent Past, Current & Future Analysis for Antibody Drug Conjugates Contract Manufacturing by Linker - Cleavable Linker and Non-Cleavable Linker - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Antibody Drug Conjugates Contract Manufacturing by Linker - Cleavable Linker and Non-Cleavable Linker Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: UK 15-Year Perspective for Antibody Drug Conjugates Contract Manufacturing by Linker - Percentage Breakdown of Value Sales for Cleavable Linker and Non-Cleavable Linker for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 77: Rest of Europe Recent Past, Current & Future Analysis for Antibody Drug Conjugates Contract Manufacturing by Condition Type - Myeloma Condition, Lymphome Condition and Other Conditions - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Rest of Europe Historic Review for Antibody Drug Conjugates Contract Manufacturing by Condition Type - Myeloma Condition, Lymphome Condition and Other Conditions Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Rest of Europe 15-Year Perspective for Antibody Drug Conjugates Contract Manufacturing by Condition Type - Percentage Breakdown of Value Sales for Myeloma Condition, Lymphome Condition and Other Conditions for the Years 2015, 2025 & 2030
    • TABLE 80: Rest of Europe Recent Past, Current & Future Analysis for Antibody Drug Conjugates Contract Manufacturing by Linker - Cleavable Linker and Non-Cleavable Linker - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Rest of Europe Historic Review for Antibody Drug Conjugates Contract Manufacturing by Linker - Cleavable Linker and Non-Cleavable Linker Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: Rest of Europe 15-Year Perspective for Antibody Drug Conjugates Contract Manufacturing by Linker - Percentage Breakdown of Value Sales for Cleavable Linker and Non-Cleavable Linker for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Antibody Drug Conjugates Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 83: Asia-Pacific Recent Past, Current & Future Analysis for Antibody Drug Conjugates Contract Manufacturing by Condition Type - Myeloma Condition, Lymphome Condition and Other Conditions - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Asia-Pacific Historic Review for Antibody Drug Conjugates Contract Manufacturing by Condition Type - Myeloma Condition, Lymphome Condition and Other Conditions Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Asia-Pacific 15-Year Perspective for Antibody Drug Conjugates Contract Manufacturing by Condition Type - Percentage Breakdown of Value Sales for Myeloma Condition, Lymphome Condition and Other Conditions for the Years 2015, 2025 & 2030
    • TABLE 86: Asia-Pacific Recent Past, Current & Future Analysis for Antibody Drug Conjugates Contract Manufacturing by Linker - Cleavable Linker and Non-Cleavable Linker - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Asia-Pacific Historic Review for Antibody Drug Conjugates Contract Manufacturing by Linker - Cleavable Linker and Non-Cleavable Linker Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Asia-Pacific 15-Year Perspective for Antibody Drug Conjugates Contract Manufacturing by Linker - Percentage Breakdown of Value Sales for Cleavable Linker and Non-Cleavable Linker for the Years 2015, 2025 & 2030
  • REST OF WORLD
    • TABLE 89: Rest of World Recent Past, Current & Future Analysis for Antibody Drug Conjugates Contract Manufacturing by Condition Type - Myeloma Condition, Lymphome Condition and Other Conditions - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Rest of World Historic Review for Antibody Drug Conjugates Contract Manufacturing by Condition Type - Myeloma Condition, Lymphome Condition and Other Conditions Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Rest of World 15-Year Perspective for Antibody Drug Conjugates Contract Manufacturing by Condition Type - Percentage Breakdown of Value Sales for Myeloma Condition, Lymphome Condition and Other Conditions for the Years 2015, 2025 & 2030
    • TABLE 92: Rest of World Recent Past, Current & Future Analysis for Antibody Drug Conjugates Contract Manufacturing by Linker - Cleavable Linker and Non-Cleavable Linker - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of World Historic Review for Antibody Drug Conjugates Contract Manufacturing by Linker - Cleavable Linker and Non-Cleavable Linker Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Rest of World 15-Year Perspective for Antibody Drug Conjugates Contract Manufacturing by Linker - Percentage Breakdown of Value Sales for Cleavable Linker and Non-Cleavable Linker for the Years 2015, 2025 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!